Literature DB >> 204584

The frequency of occurrence of feline leukaemia virus subgroups in cats.

O Jarrett, W D Hardy, M C Golder, D Hay.   

Abstract

Feline leukaemia viruses (FeLV) were isolated from cats in Glasgow and New York with lymphosarcoma and from apparently healthy carrier cats. The subgroup composition of each isolate was determined. All isolates contained FeLV of subgroup A(FeLV-A) and a high proportion also contained subgroup B virus (FeLV-B). Virus of subgroup C (FeLV-C) was rare and occurred in association with FeLV-A and, in some isolates, with FeLV-B as well. The same pattern was observed in isolates from British and American cats. The frequency of FeLV subgroups was different in cats with lymphosarcoma and in healthy carrier cats. In cats with lymphosarcoma, 42% had FeLV-A and 58% had FeLV-AB; there was no obvious correlation between virus subgroup and type of disease. In FeLV-positive healthy cats, 65% had FeLV-A and 33% had FeLV-AB. FeLV-C was isolated only from cats with disease. The healthy carrier cats were from multiple-cat households (MCH). Two distinct types of FeLV-infected MCH were found: MCH-A in which the carrier cats yielded only FeLV-A, and MCH-AB in which cats with either FeLV-A or FeLV-AB were present. In MCH-AB half of the cats had FeLV-A and half had FeLV-AB. Overall, the proportion of cats in MCH which were viraemic with FeLV was 42%. However, there was a marked difference in the prevalence of carrier cats in each type of MCH: in MCH-A, 28% were FeLV-positive while in MCH-AB, 53% were viraemic.

Entities:  

Mesh:

Year:  1978        PMID: 204584     DOI: 10.1002/ijc.2910210314

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  44 in total

1.  Host range and receptor binding properties of vectors bearing feline leukemia virus subgroup B envelopes can be modulated by envelope sequences outside of the receptor binding domain.

Authors:  Peggy Ho Faix; Steven A Feldman; Julie Overbaugh; Maribeth V Eiden
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  Strong sequence conservation among horizontally transmissible, minimally pathogenic feline leukemia viruses.

Authors:  P R Donahue; E A Hoover; G A Beltz; N Riedel; V M Hirsch; J Overbaugh; J I Mullins
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

3.  Nucleotide sequences of a feline leukemia virus subgroup A envelope gene and long terminal repeat and evidence for the recombinational origin of subgroup B viruses.

Authors:  M A Stewart; M Warnock; A Wheeler; N Wilkie; J I Mullins; D E Onions; J C Neil
Journal:  J Virol       Date:  1986-06       Impact factor: 5.103

4.  Genomic stability of gibbon oncornavirus.

Authors:  L Sun; T G Kawakami; S I Matoba
Journal:  J Virol       Date:  1978-12       Impact factor: 5.103

5.  Genetic determinants of feline leukemia virus-induced lymphoid tumors: patterns of proviral insertion and gene rearrangement.

Authors:  C Tsatsanis; R Fulton; K Nishigaki; H Tsujimoto; L Levy; A Terry; D Spandidos; D Onions; J C Neil
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

6.  Feline Pit2 functions as a receptor for subgroup B feline leukemia viruses.

Authors:  M M Anderson; A S Lauring; S Robertson; C Dirks; J Overbaugh
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  A putative thiamine transport protein is a receptor for feline leukemia virus subgroup A.

Authors:  Ramon Mendoza; Maria M Anderson; Julie Overbaugh
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

8.  The association of viruses with urveal melanoma.

Authors:  D M Albert
Journal:  Trans Am Ophthalmol Soc       Date:  1979

Review 9.  Endogenous env elements: partners in generation of pathogenic feline leukemia viruses.

Authors:  P Roy-Burman
Journal:  Virus Genes       Date:  1995       Impact factor: 2.332

10.  Comparative analysis of the genomes of feline leukemia viruses.

Authors:  Z F Rosenberg; F S Pedersen; W A Haseltine
Journal:  J Virol       Date:  1980-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.